Design, development and evaluation of curcumin (Curcuma longa) encapsulated phospholipid nanocarrier to enhance solubility and improve efficacy in MCF-7 cell line by Quality by Design.

IF 1 Q4 PHARMACOLOGY & PHARMACY

Annales pharmaceutiques francaises Pub Date : 2025-07-10 DOI:10.1016/j.pharma.2025.07.004

Vaibhav Bhadange, Supriya Jogdand, Ankita Kawtikwar, Pravin Kawtikwar

{"title":"Design, development and evaluation of curcumin (Curcuma longa) encapsulated phospholipid nanocarrier to enhance solubility and improve efficacy in MCF-7 cell line by Quality by Design.","authors":"Vaibhav Bhadange, Supriya Jogdand, Ankita Kawtikwar, Pravin Kawtikwar","doi":"10.1016/j.pharma.2025.07.004","DOIUrl":null,"url":null,"abstract":"<p><p>Lipid-based excipients are increasingly used to enhance the stability of innovative drug delivery systems. Phospoholipid nanocarriers, a botanical formulation, are used to build lipophilic molecular complexes, improving stability, absorption, and bioavailability. Turmeric (Curcuma longa) contains curcumin, which has poor bioavailability due to its solubility and wettability. Hence the study was designed to enhance the solubility of curcumin by phospholipid complexation. The curcumin-encapsulated phospholipid nanocarriers (Ccm-PNs) were developed by solvent evaporation method, and the formula was optimized using a Box-Behnekn design based on QbD. Physicochemical properties and functional characterization were done by accessing particle size, entrapment efficiency, in vitro drug release. The adenocarcinoma breast cell line (MCF-7) was used for cytotoxicity investigation of Ccm-PNs. It showed lower particle size and stable zeta potential values, and their compatibility with excipients was confirmed through DSC and FTIR studies. They also demonstrated higher entrapment and in vitro drug release over 48 hours. The cytotoxicity study showed improved efficacy than pure curcumin solution. In conclusion, overall results shows that phospholipid nanocarriers have the ability to enhance therapeutic efficacy and bioavailability.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":" ","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales pharmaceutiques francaises","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.pharma.2025.07.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Lipid-based excipients are increasingly used to enhance the stability of innovative drug delivery systems. Phospoholipid nanocarriers, a botanical formulation, are used to build lipophilic molecular complexes, improving stability, absorption, and bioavailability. Turmeric (Curcuma longa) contains curcumin, which has poor bioavailability due to its solubility and wettability. Hence the study was designed to enhance the solubility of curcumin by phospholipid complexation. The curcumin-encapsulated phospholipid nanocarriers (Ccm-PNs) were developed by solvent evaporation method, and the formula was optimized using a Box-Behnekn design based on QbD. Physicochemical properties and functional characterization were done by accessing particle size, entrapment efficiency, in vitro drug release. The adenocarcinoma breast cell line (MCF-7) was used for cytotoxicity investigation of Ccm-PNs. It showed lower particle size and stable zeta potential values, and their compatibility with excipients was confirmed through DSC and FTIR studies. They also demonstrated higher entrapment and in vitro drug release over 48 hours. The cytotoxicity study showed improved efficacy than pure curcumin solution. In conclusion, overall results shows that phospholipid nanocarriers have the ability to enhance therapeutic efficacy and bioavailability.

查看原文本刊更多论文

姜黄素包封磷脂纳米载体在MCF-7细胞中增强溶解度和提高疗效的设计、开发与评价

脂基赋形剂越来越多地用于提高创新药物输送系统的稳定性。磷脂纳米载体是一种植物制剂，用于构建亲脂分子复合物，提高稳定性、吸收性和生物利用度。姜黄（Curcuma longa）含有姜黄素，由于其溶解度和润湿性，姜黄素的生物利用度较差。因此，本研究旨在通过磷脂络合提高姜黄素的溶解度。采用溶剂蒸发法制备了姜黄素包封磷脂纳米载体（Ccm-PNs），并采用基于QbD的Box-Behnekn设计对其配方进行了优化。通过粒径、包封效率、体外释药等指标对其理化性质和功能进行表征。采用乳腺腺癌细胞系MCF-7对Ccm-PNs进行细胞毒性研究。其粒径较小，zeta电位稳定，并通过DSC和FTIR研究证实了与辅料的配伍性。它们还表现出更高的包裹性和48小时的体外药物释放。细胞毒性研究表明，姜黄素溶液的效果优于纯姜黄素溶液。综上所述，磷脂纳米载体具有提高治疗效果和生物利用度的能力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annales pharmaceutiques francaises PHARMACOLOGY & PHARMACY-

CiteScore

1.70

自引率

7.70%

发文量

期刊介绍： This journal proposes a scientific information validated and indexed to be informed about the last research works in all the domains interesting the pharmacy. The original works, general reviews, the focusing, the brief notes, subjected by the best academics and the professionals, propose a synthetic approach of the last progress accomplished in the concerned sectors. The thematic Sessions and the – life of the Academy – resume the communications which, presented in front of the national Academy of pharmacy, are in the heart of the current events.